Key Takeaway: Skye presented a poster at ECO 2025 showcasing preclinical models that highlight the effectiveness of peripheral CB1 inhibition in promoting weight loss. The study utilized clinical pharmacokinetic and pharmacodynamic models to demonstrate these findings. This research suggests a potential therapeutic avenue for weight management.
Price reaction · baseline $2.05 (2025-05-12 close) · hit pre-market · clean, no other SKYE news in the window
day 0 close
-5.4%
day 1
-7.3%
day 3 · peak
-8.8%
Market Sentiment Analysis
POSITIVE FACTORS
Presentation of promising preclinical models.
Demonstrates potential for weight loss through CB1 inhibition.
Engagement at a significant conference (ECO 2025).
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
24.3%
average across 4 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
Nimacimab
Phase 2 · Obesity
Full Press Release Details
All
Primers
Perspectives
Progress
Press
Preclinical Models Highlight Utility of Peripheral CB1 Inhibition
Date published:
May 13, 2025 9:00 am PDT
Share
Related Documents:
Poster: The Sufficiency of Peripheral CB1 Inhibition to Promote Weight Loss
At ECO 2025, Skye presented its poster: “Demonstrating the sufficiency of peripheral CB1 inhibition to promote weight loss using clinical pharmacokinetic and pharmacodynamic models.”
Frequently Asked Questions
What was presented at ECO 2025?
Skye presented a poster on preclinical models demonstrating peripheral CB1 inhibition's effectiveness in promoting weight loss.
What models were used in Skye's study?
The study utilized clinical pharmacokinetic and pharmacodynamic models.
What is the significance of peripheral CB1 inhibition?
Peripheral CB1 inhibition shows potential as a therapeutic approach for weight management.